Log in

Transgene relies on its clinical trials for 2018

Biotech company Transgene said Thursday, when it published its results, that it expected 2018 clinical results for five of its seven products currently tested.

The third quarter of 2017 was marked by the launch of two clinical trials, one to treat liver cancers, the other to those of the head and neck.

In September, Transgene also received approval from the FDA to launch a trial of a lung cancer product.

On the financial side, the Alsatian company reported a cash position of 40 million euros at 30 September 2017, against 56,2 million at 31 December 2016.

"Our cash position allows us to confirm our financial visibility until the end of 2018," said Philippe Archinard, CEO of the company.

Transgene confirmed expecting a decrease in cash of approximately 30 million euros over the whole year.

The biotechnology company specializes in the development of immunotherapy products against cancers. It works especially on oncolytic viruses that make it possible to increase the destruction of the tumors.

a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )

  group    administrators A3P
& Project Managers

letter   newsletter A3P